Oric Pharmaceuticals, Inc. ORIC Balance Sheet Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $56.4M+14.3% | $45.67M-23.1% | $49.67M+12.3% | $75.86M+52.2% | $49.33M-12.5% | ||
| $225.54M+46.1% | $235.82M+20.0% | $237.47M+4.1% | $206.65M-12.6% | $154.39M-40.7% | ||
| $8.3M+7.7% | $6.98M+10.9% | $8.45M+19.8% | $8.61M+5.1% | $7.71M+5.5% | ||
| $290.23M+37.3% | $288.47M+10.0% | $295.59M+5.8% | $291.12M-1.2% | $211.43M-34.8% | ||
| $2.15M-28.9% | $2.42M-17.4% | $2.56M-17.2% | $2.76M-4.0% | $3.02M+7.9% | ||
| $6.6M-21.1% | $7.25M-19.2% | $7.13M-25.4% | $7.76M-16.6% | $8.37M-9.2% | ||
| $137.78M+588% | $110.76M— | $125.91M+1,159% | $45.22M+104% | $20.04M+36.4% | ||
| $436.76M+79.8% | $408.89M+49.2% | $431.19M+42.7% | $346.86M+5.5% | $242.86M-30.8% | ||
| $2.9M-43.9% | $3.82M+147% | $2.9M-31.7% | $3.13M+35.6% | $5.16M+72.7% | ||
| $14.88M+19.4% | $16.59M-28.8% | $17.28M+1.6% | $14.92M-13.4% | $12.46M+1.9% | ||
| $3.3M+2.6% | $3.33M+4.6% | $3.3M+5.8% | $3.27M+18.2% | $3.21M+15.8% | ||
| $17.77M+0.9% | $20.42M-17.8% | $20.18M-5.0% | $18.05M-7.6% | $17.62M+15.8% | ||
| $3.43M-37.6% | $4.11M-33.4% | $4.09M-40.0% | $4.81M-30.9% | $5.5M-20.6% | ||
| $21.21M-8.3% | $24.53M-20.9% | $24.27M-13.5% | $22.86M-13.7% | $23.12M+4.4% | ||
| $0— | $0— | $0— | $0— | $0— | ||
| $11K+57.1% | $11K+57.1% | $11K+57.1% | $9K+28.6% | $7K0.0% | ||
| $1.14B+40.8% | $1.08B+33.6% | $1.07B+33.5% | $952.95M+19.9% | $812.32M+3.0% | ||
| -$728.01M-22.8% | -$692.24M-23.0% | -$661.74M-25.7% | -$629.15M-27.9% | -$592.8M-28.9% | ||
| -$290K-239% | $786K+107% | $615K-14.8% | $187K+173% | $209K+229% | ||
| $415.56M+89.1% | $384.36M+58.1% | $406.92M+48.5% | $324M+7.1% | $219.74M-33.1% | ||
| $436.76M+79.8% | $408.89M+49.2% | $431.19M+42.7% | $346.86M+5.5% | $242.86M-30.8% | ||
| $225.54M+46.1% | $235.82M+20.0% | $237.47M+4.1% | $206.65M-12.6% | $154.39M-40.7% | ||
| $6.6M-21.1% | $7.25M-19.2% | $7.13M-25.4% | $7.76M-16.6% | $8.37M-9.2% | ||
| $137.78M+588% | $110.76M— | $125.91M+1,159% | $45.22M+104% | $20.04M+36.4% | ||
| $6.6M-21.1% | $7.25M-19.2% | $7.13M-25.4% | $7.76M-16.6% | $8.37M-9.2% | ||
| $6.6M-21.1% | $7.25M-19.2% | $7.13M-25.4% | $7.76M-16.6% | $8.37M-9.2% | ||
| $14.88M+19.4% | $16.59M-28.8% | $17.28M+1.6% | $14.92M-13.4% | $12.46M+1.9% | ||
| $14.88M+19.4% | $16.59M-28.8% | $17.28M+1.6% | $14.92M-13.4% | $12.46M+1.9% | ||
| $3.3M+2.6% | $7.44M-20.5% | $3.3M+5.8% | $3.27M+18.2% | $3.21M+15.8% | ||
| $1.14B+40.8% | $1.08B+33.6% | $1.07B+33.5% | $952.95M+19.9% | $812.32M+3.0% | ||
| $11K+57.1% | $11K+57.1% | $11K+57.1% | $9K+28.6% | $7K0.0% | ||
| $0— | $0— | $0— | $0— | $0— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Oric Pharmaceuticals, Inc.'s total assets?
- Oric Pharmaceuticals, Inc. (ORIC) holds $436.8M in total assets, up 79.8% year over year.
- How much debt does Oric Pharmaceuticals, Inc. have?
- Oric Pharmaceuticals, Inc. carries $3.3M in total debt against $415.6M of shareholders' equity, a debt-to-equity ratio of 0.01.
- How much cash does Oric Pharmaceuticals, Inc. have?
- Oric Pharmaceuticals, Inc. holds $56.4M in cash and equivalents.
- Can Oric Pharmaceuticals, Inc. cover its short-term obligations?
- Its current ratio is 16.33 — current assets exceed current liabilities.
- Where does Oric Pharmaceuticals, Inc.'s balance sheet data come from?
- Every line is extracted from Oric Pharmaceuticals, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.